Last reviewed · How we verify

NSAID therapy

Rabin Medical Center · FDA-approved active Small molecule

NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Inflammation and fever, Rheumatoid arthritis.

At a glance

Generic nameNSAID therapy
SponsorRabin Medical Center
Drug classNon-steroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPain Management, Rheumatology, Cardiovascular
PhaseFDA-approved

Mechanism of action

NSAIDs block COX-1 and/or COX-2 enzymes, which catalyze the production of prostaglandins and thromboxanes from arachidonic acid. By reducing these inflammatory mediators, NSAIDs provide analgesic, anti-inflammatory, and antipyretic effects. Different NSAIDs vary in their selectivity for COX-1 versus COX-2, which influences both efficacy and side effect profiles.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: